Literature DB >> 25851028

Differentiation of focal nodular hyperplasia from hepatocellular adenoma: Role of the quantitative analysis of gadobenate dimeglumine-enhanced hepatobiliary phase MRI.

Marion Roux1, Frederic Pigneur1, Julien Calderaro2,3, Laurence Baranes1, Mélanie Chiaradia1,2, Lambros Tselikas1, Thomas Decaens2,4, Charlotte Costentin2,4, Alexis Laurent2,5, Daniel Azoulay2,5, Ariane Mallat2,4, Elie-Serge Zafrani2,3, Alain Rahmouni1,2, Alain Luciani1,2,6.   

Abstract

PURPOSE: To determine the value of quantitative analysis of the hepatobiliary phase (HBP) in gadobenate dimeglumine (Gd-BOPTA)-enhanced magnetic resonance imaging (MRI) to differentiate focal nodular hyperplasia (FNH) from hepatocellular adenoma (HCA).
MATERIALS AND METHODS: Thirty-eight patients bearing 67 lesions (40 FNH; 27 HCA) were retrospectively included in this Institutional Review Board-approved study. The same volumetric interpolated breath-hold examination (VIBE) T1 -weighted sequences were performed before and after contrast injection on a 1.5T MRI, with HBP images acquired with a mean delay of 80 minutes (range 60-120 min). After a visual assessment of lesions enhancement (qualitative HBP analysis), the HBP signal intensity ratio (SIR) and the lesion-to-liver contrast enhancement ratio (LLCER) were calculated for each lesion by two observers (Mann-Whitney test). The sensitivities, specificities (receiver operating characteristic [ROC] curve analysis) and interobserver correlation (intraclass coefficient, ICC) of quantitative HBP analysis were determined.
RESULTS: All FNH and 44.4% of HCA appeared hyper- or isointense relative to the adjacent liver on qualitative HBP analysis. The mean SIR (P < 0.01) and LLCER (P < 0.0001) of FNH were significantly higher than that of HCA. The area under the ROC curve for the differentiation of FNH from HCA with LLCER was 0.98 for both observers. With a cutoff value of -0.3%-observer 1 with highest experience- LLCER assessment provided respective sensitivity and specificity values of 100% and 96.2% for the differentiation of FNH from HCA. The ICC was 0.7 for SIR measurements and 0.8 for LLCER measurements.
CONCLUSION: Quantitative LLCER assessment allows an accurate differentiation of FNH from HCA, even in hyper- or isointense HCA on HBP images.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  Gd-BOPTA; MRI; focal nodular hyperplasia; hepatocellular adenoma; liver; quantitative analysis

Mesh:

Substances:

Year:  2015        PMID: 25851028     DOI: 10.1002/jmri.24897

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  8 in total

1.  Iso- or hyperintensity of hepatocellular adenomas on hepatobiliary phase does not always correspond to hepatospecific contrast-agent uptake: importance for tumor subtyping.

Authors:  Edouard Reizine; Maxime Ronot; Frederic Pigneur; Yvonne Purcell; Sebastien Mulé; Marco Dioguardi Burgio; Julien Calderaro; Giuliana Amaddeo; Alexis Laurent; Valérie Vilgrain; Alain Luciani
Journal:  Eur Radiol       Date:  2019-04-01       Impact factor: 5.315

2.  Prediction of early recurrence of hepatocellular carcinoma after resection based on Gd-EOB-DTPA enhanced magnetic resonance imaging: a preliminary study.

Authors:  Qi-Yu Zhao; Shi-Shun Liu; Ming-Xin Fan
Journal:  J Gastrointest Oncol       Date:  2022-04

3.  Quantitative correlation between uptake of Gd-BOPTA on hepatobiliary phase and tumor molecular features in patients with benign hepatocellular lesions.

Authors:  Edouard Reizine; Giuliana Amaddeo; Frederic Pigneur; Laurence Baranes; François Legou; Sebastien Mulé; Benhalima Zegai; Vincent Roche; Alexis Laurent; Alain Rahmouni; Julien Calderaro; Alain Luciani
Journal:  Eur Radiol       Date:  2018-05-02       Impact factor: 5.315

4.  Hepatospecific MR contrast agent uptake on hepatobiliary phase can be used as a biomarker of marked β-catenin activation in hepatocellular adenoma.

Authors:  E Reizine; M Ronot; M Ghosn; J Calderaro; N Frulio; P Bioulac-Sage; H Trillaud; V Vilgrain; V Paradis; A Luciani
Journal:  Eur Radiol       Date:  2020-11-04       Impact factor: 5.315

5.  Identification of Arterial Hyperenhancement in CT and MRI in Patients with Hepatocellular Carcinoma: Value of Unenhanced Images.

Authors:  Mimi Kim; Tae Wook Kang; Dong Ik Cha; Kyoung Mi Jang; Young Kon Kim; Seong Hyun Kim; Dong Hyun Sinn; Kyunga Kim
Journal:  Korean J Radiol       Date:  2019-02       Impact factor: 3.500

6.  Efficacy comparison of multi-phase CT and hepatotropic contrast-enhanced MRI in the differential diagnosis of focal nodular hyperplasia: a prospective cohort study.

Authors:  Tomasz K Nowicki; Karolina Markiet; Ewa Izycka-Swieszewska; Katarzyna Dziadziuszko; Michal Studniarek; Edyta Szurowska
Journal:  BMC Gastroenterol       Date:  2018-01-15       Impact factor: 3.067

Review 7.  New insights in the management of Hepatocellular Adenoma.

Authors:  Anne J Klompenhouwer; Robert A de Man; Marco Dioguardi Burgio; Valerie Vilgrain; Jessica Zucman-Rossi; Jan N M Ijzermans
Journal:  Liver Int       Date:  2020-06-11       Impact factor: 5.828

Review 8.  Molecular classification of hepatocellular adenomas: impact on clinical practice.

Authors:  Anne-Laure Védie; Olivier Sutter; Marianne Ziol; Jean-Charles Nault
Journal:  Hepat Oncol       Date:  2018-04-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.